Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    30
  • sponsor
    University of Virginia
Updated on 3 November 2021
haemostasis
cardiopulmonary bypass
fibrinogen
cryoprecipitate

Summary

The aim of the current pilot study proposal is to compare the use of the purified human fibrinogen concentrate (Fibryga, Octapharma USA) to cryoprecipitate for the treatment of cardiopulmonary bypass (CPB)-associated bleeding in pediatric cardiac patients in whom fibrinogen supplementation is indicated.

The investigators' hypothesis is that fibrinogen concentrate will be as effective as cryoprecipitate in achieving adequate hemostasis after separation from CPB in pediatric cardiac surgery patients.

Study Design: this will be a single-center, prospective, randomized, active-control study in pediatric (24 months of age or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM). Informed consent will be obtained from a parent or a legal guardian prior to surgery and anesthesia. Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group):

  1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or
  2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who received FC).

The results of this study will be used for publication as well as the first stage towards a significantly larger randomized multi-center trial (see below).

Based on the results of this pilot study the investigators plan to conduct a large multi-center, randomized active-control non-inferiority trial in the future, comparing the use of FC to cryoprecipitate in a much larger cohort of pediatric patients undergoing cardiac surgery with CPB. Ultimately, the results of this trial are likely to improve the care of pediatric cardiac surgical patients experiencing post-CPB bleeding, an under-studied yet high-risk patient population.

Description

Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group):

  1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or
  2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who initially received FC).

Data to be obtained:

  1. Demographic/preoperative data:
    • age in days/months (all participants to be 24 months of age or younger)
    • gender
    • weight
    • preoperative diagnosis
    • RACHS classification
    • surgery type & date (Norwood, arterial switch, truncus arteriosus, Glenn, anomalous pulmonary venous return, AV canal, tetralogy of Fallot, VSD closure, etc)
    • preoperative PT/INR/aPTT/hemoglobin level/ hematocrit/ platelet count/ WBC count/ fibrinogen level (Clauss method)
    • metabolic panel (sodium, BUN, creatinine, glucose, calcium, bicarbonate, Liver function tests)
  2. Intra-operative Data:
    • CPB time & aortic cross clamp time
    • Use of hypothermic circulatory arrest (ice packs placed on the head)
    • ROTEM: Extem (CT/A10/A20/MCF) and Fibtem (A10/A20/MCF) at the following time points: baseline (after induction of anesthesia), 20 min prior to separation from CPB and 10 minutes after completion of fibrinogen concentrate/cryoprecipitate administration
    • Platelet count prior to separation from CPB
    • was ATIII administered? (thrombate)
    • Transfusion requirements: PRBC/Cell Saver/FFP/PLT/ cryoprecipitate - to be collected as number of units per each product, not volume. (for PLT - was it pooled PLT or single donor apheresis)
    • was rFVIIa given (factor seven, novoseven).
    • Need for ECMO support after separation trial from CPB
    • Was the chest left open?
  3. Postoperative Data
    • PT/aPTT/INR/platelet count/ fibrinogen level/ Hgb level/HCT level on admission to the ICU
    • ROTEM parameters
    • Liver and kidney function tests on admission to the ICU
    • Bleeding (Chest drain output until 48 hours after surgery)
    • Need for additional transfusion (RBC/FFP/platelets/cryoprecipitate) until 7 days after surgery.
    • Factor VIIa administration
    • re-exploration for bleeding/tamponade (need for postoperative chest re-exploration or re- operation either in the ICU or in the OR due to excessive postoperative bleeding and/or cardiac tamponade)
    • Need for initiation of ECMO support in the ICU postoperatively
    • Duration of postoperative intubation
    • AKI (AKIN criteria)
    • Stroke/seizures > 24 hours post-operatively
    • Infection (sternal wound infection/mediastinitis/pneumonia/sepsis)
    • Thromboembolic complications (shunt thrombosis/DVT/PE)
    • ICU length of stay
    • Hospital length of stay
    • In hospital mortality

Details
Condition Pediatric HD, Hemorrhage
Treatment Fibrinogen, Cryoprecipitate
Clinical Study IdentifierNCT04376762
SponsorUniversity of Virginia
Last Modified on3 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

pediatric (age 24 months or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM)

Exclusion Criteria

gestational age < 33 weeks at birth
gestational age < 35 weeks on the day of surgery
emergency surgery
patient or parent history of coagulopathy/clotting abnormalities
patient history of thrombophilia
refusal to participate in the study
known severe allergic reaction/anaphylaxis to fibrinogen concentrate
administration of fibrinogen concentrate or cryoprecipitate in the 24 hours prior to surgery
baseline fibrinogen level higher than 300 mg/dL (to avoid the risk of increasing the fibrinogen level above the normal upper level of 400 mg/dL)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note